Shareholder Alert: The Ademi Firm investigates whether Quipt Home Medical Corp. is obtaining a Fair Price for its Public Shareholders

16.12.25 16:47 Uhr

Werte in diesem Artikel

MILWAUKEE, Dec. 16, 2025 /PRNewswire/ -- The Ademi Firm is investigating Quipt (Nasdaq: QIPT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Kingswood and Forager.

Ademi & Fruchter Logo (PRNewsfoto/Ademi LLP)

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Quipt shareholders will receive $3.65 per share, valuing Quipt at approximately $260 million, including Quipt's existing outstanding debt. Quipt insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Quipt by imposing a significant penalty if Quipt accepts a competing bid. We are investigating the conduct of the Quipt board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-quipt-home-medical-corp-is-obtaining-a-fair-price-for-its-public-shareholders-302643443.html

SOURCE Ademi LLP

Ausgewählte Hebelprodukte auf Protech Home Medical

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Protech Home Medical

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Protech Home Medical Corp Registered Shs

Wer­bung